Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

Inclusion criteria : * Participants with T2D treated with a Sulfonylurea (≥half the maximum recommended dose as per local label or maximum tolerated dose \[documented\]) as monotherapy or in combination with Metformin (≥1500 mg per day or maximum tolerated dose \[documented\]) each at a stable dose for at least 12 weeks without a dose adjustment before screening. * Signed written informed consent. Exclusion criteria: * At the time of screening, age \<18 years or \< legal age of majority, whichever is greater. * Body Mass Index (BMI) ≤20 or \>45 kilograms per meter square (kg/m\^2) at Screening. * Hemoglobin A1c (HbA1c) \<7% or HbA1c \>10% via central lab test at screening. * Fasting plasma glucose (FPG) \>15 mmol/L (270 mg/dL) measured by the central laboratory at screening (Visit 1), and confirmed (\>15 mmol/L \[270 mg/dL\]) by a repeat test before randomization. * Women of childbearing potential with no effective contraceptive method. * Treated with an antidiabetic pharmacological regimen other than a Sulfonylurea at a stable dose with or without Metformin within 12 weeks preceding the screening visit. * Previous insulin use \>1 month (at any time, aside from treatment of gestational diabetes). * History of prior gastric surgical procedure including gastric banding or inflammatory bowel disease within 3 years before the Screening Visit. * History of diabetic ketoacidosis or nonketotic hyperosmolar coma within 12 weeks prior to the Screening Visit. * History of severe hypoglycemia within 6 months prior to the Screening visit. * Systolic blood pressure (SBP) \>180 millimeter per mercury (mmHg) or diastolic blood pressure (DBP) \>100 mmHg or history of hypertensive emergency. * Aspartate aminotransferase and/or alanine aminotransferase: \>3 times the upper limit of the normal laboratory range (ULN). * Total bilirubin: \>1.5 times ULN (except in case of Gilbert's syndrome). * Use of systemic glucocorticoids (excluding topical or ophthalmic, application or inhaled forms) for more than 10 consecutive days within 90 days prior to the Screening Visit. * Pregnancy, breastfeeding. * Participants is unwilling to perform self-monitoring of blood glucose (SMBG), and complete the participant's diary as required per protocol. The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.